New board member at DOR BioPharma
This article was originally published in Scrip
Executive Summary
Gregg Lapointe has been appointed to the board of DOR BioPharma. Mr Lapointe is currently CEO of Sigma-Tau Pharmaceuticals, which is DOR's North American partner for OrBec (oral beclometasone dipropionate) and its largest shareholder.